Want to see JP:6678 full AI Analyst Report?
6678 Stock Chart & Stats
¥2245.00
-¥13.00(-0.72%)
At close: 4:00 PM EST
¥2245.00
-¥13.00(-0.72%)
Day’s Range― - ―
52-Week Range¥1,850.00 - ¥2,787.00
Previous CloseN/A
Volume3.70K
Average Volume (3M)5.40K
Market Cap
¥18.44B
Enterprise Value¥4.43K
Total Cash (Recent Filing)¥8.98B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)12.2
Beta0.57
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.96%
Share Statistics
EPS (TTM)155.28
Shares Outstanding8,760,000
10 Day Avg. Volume4,730
30 Day Avg. Volume5,400
Financial Highlights & Ratios
PEG Ratio2.14
Price to Book (P/B)1.12
Price to Sales (P/S)1.44
P/FCF Ratio15.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free structure reduces refinancing and interest-rate risk while preserving financial flexibility. The substantial equity base should help Techno Medica fund operations, product development, and investment through weaker business cycles.
Sustained Gross MarginsConsistently strong gross margins indicate that the IVD instrument and consumables portfolio retains meaningful economic value. This provides a durable cushion for research, manufacturing, and distribution costs even when revenue growth varies.
Recent Revenue And Earnings ReboundThe latest rebound shows that demand can reaccelerate after weaker periods, supporting the company’s ability to regain scale in clinical testing markets. Strong EPS growth also suggests operating leverage when revenue momentum improves.
Bears Say
Uneven Revenue GrowthRepeated year-to-year revenue declines indicate that demand and order timing are not consistently expanding. This limits visibility into the company’s long-term growth path and makes future earnings more dependent on periodic recoveries.
Volatile Cash GenerationAlthough free cash flow generally tracks net income, large swings in operating and free cash flow reduce predictability. Volatility can complicate inventory, capital allocation, and shareholder-return planning even without balance-sheet leverage.
Modest Returns On EquityMid-to-high single-digit ROE suggests the substantial equity base is not being converted into especially strong shareholder returns. With no debt leverage, improving asset productivity and profitability will be important for stronger compounding.
Techno Medica Co., Ltd. News
6678 FAQ
What was Techno Medica Co., Ltd.’s price range in the past 12 months?
Techno Medica Co., Ltd. lowest stock price was ¥1850.00 and its highest was ¥2787.00 in the past 12 months.
What is Techno Medica Co., Ltd.’s market cap?
Techno Medica Co., Ltd.’s market cap is ¥18.44B.
When is Techno Medica Co., Ltd.’s upcoming earnings report date?
Techno Medica Co., Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 80 days.
How were Techno Medica Co., Ltd.’s earnings last quarter?
Techno Medica Co., Ltd. released its earnings results on Aug 05, 2026. The company reported ¥23.86 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Techno Medica Co., Ltd. overvalued?
According to Wall Street analysts Techno Medica Co., Ltd.’s price is currently Overvalued.
Does Techno Medica Co., Ltd. pay dividends?
Techno Medica Co., Ltd. pays a Annually dividend of ¥93 which represents an annual dividend yield of 5.96%. See more information on Techno Medica Co., Ltd. dividends here
What is Techno Medica Co., Ltd.’s EPS estimate?
Techno Medica Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Techno Medica Co., Ltd. have?
Techno Medica Co., Ltd. has 8,760,000 shares outstanding.
What happened to Techno Medica Co., Ltd.’s price movement after its last earnings report?
Techno Medica Co., Ltd. reported an EPS of ¥23.86 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.013%.
Which hedge fund is a major shareholder of Techno Medica Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6678
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Techno Medica Co., Ltd.
Techno Medica Co., Ltd. is a Japanese company that specializes in the entire lifecycle of in-vitro diagnostic analyzers, covering their research, development, manufacturing, distribution, and international trade. Their product portfolio includes automated systems for test tube preparation, urine aliquot, and RFID-based management solutions for both biological specimens and blood transfusions. The company also supplies a diverse range of analytical instruments for measuring blood gases, electrolytes, erythrocyte sedimentation rates, nutrient levels, sugar and acid content, and for performing urine chemistry tests. Furthermore, Techno Medica provides electronic medical charting systems, various pre-analytical devices, essential consumables, and comprehensive after-sales support. Established in 1987, the company's main office is located in Yokohama, Japan.
Technical Analysis
PHC Holdings Corp.
―
Eiken Chemical Co., Ltd.
―
Nihon Kohden Corporation
―
Japan Medical Dynamic Marketing, Inc.
―
Koken Ltd.
―